Pharmacological treatment of chronic heart failure

Rachele Adorisio; Leonardo De Luca; Joseph Rossi; Mihai Gheorghiade

doi:10.1007/s10741-006-9482-z

Pharmacological treatment of chronic heart failure

Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article

Abstract

Heart failure (HF) is associated with a high morbidity and mortality in the Western World. Our knowledge of the epidemiology, pathophysiology, and therapy has improved dramatically during the last 20 years. Pharmacological treatment, as it stands today, is a combination of preventive and symptomatic strategies. The mainstay life-saving drugs are angiotensin-converting enzyme inhibitors and β-blockers. Additional benefits are obtained when angiotensin-receptor blockers or aldosterone antagonists are added. Digitalis and/or diuretics are useful for symptom reduction. In addition, combination therapy with hydralazine and isosorbide dinitrate is recommended in African Americans.

Original language	English
Pages (from-to)	109-123
Number of pages	15
Journal	Heart Failure Reviews
Volume	11
Issue number	2
DOIs	https://doi.org/10.1007/s10741-006-9482-z
Publication status	Published - Jun 2006

Fingerprint

Keywords

β-blockers
Angiotensin-converting enzyme inhibitors
Digitalis
Diuretics
Drugs
Heart failure

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Cite this

Adorisio, R., De Luca, L., Rossi, J., & Gheorghiade, M. (2006). Pharmacological treatment of chronic heart failure. Heart Failure Reviews, 11(2), 109-123. https://doi.org/10.1007/s10741-006-9482-z

@article{a023fd2961f64900863613fe2c85c966,

title = "Pharmacological treatment of chronic heart failure",

abstract = "Heart failure (HF) is associated with a high morbidity and mortality in the Western World. Our knowledge of the epidemiology, pathophysiology, and therapy has improved dramatically during the last 20 years. Pharmacological treatment, as it stands today, is a combination of preventive and symptomatic strategies. The mainstay life-saving drugs are angiotensin-converting enzyme inhibitors and β-blockers. Additional benefits are obtained when angiotensin-receptor blockers or aldosterone antagonists are added. Digitalis and/or diuretics are useful for symptom reduction. In addition, combination therapy with hydralazine and isosorbide dinitrate is recommended in African Americans.",

keywords = "β-blockers, Angiotensin-converting enzyme inhibitors, Digitalis, Diuretics, Drugs, Heart failure",

author = "Rachele Adorisio and {De Luca}, Leonardo and Joseph Rossi and Mihai Gheorghiade",

year = "2006",

month = jun,

doi = "10.1007/s10741-006-9482-z",

language = "English",

volume = "11",

pages = "109--123",

journal = "Heart Failure Reviews",

issn = "1382-4147",

publisher = "Springer New York LLC",

number = "2",

}

TY - JOUR

T1 - Pharmacological treatment of chronic heart failure

AU - Adorisio, Rachele

AU - De Luca, Leonardo

AU - Rossi, Joseph

AU - Gheorghiade, Mihai

PY - 2006/6

Y1 - 2006/6

N2 - Heart failure (HF) is associated with a high morbidity and mortality in the Western World. Our knowledge of the epidemiology, pathophysiology, and therapy has improved dramatically during the last 20 years. Pharmacological treatment, as it stands today, is a combination of preventive and symptomatic strategies. The mainstay life-saving drugs are angiotensin-converting enzyme inhibitors and β-blockers. Additional benefits are obtained when angiotensin-receptor blockers or aldosterone antagonists are added. Digitalis and/or diuretics are useful for symptom reduction. In addition, combination therapy with hydralazine and isosorbide dinitrate is recommended in African Americans.

AB - Heart failure (HF) is associated with a high morbidity and mortality in the Western World. Our knowledge of the epidemiology, pathophysiology, and therapy has improved dramatically during the last 20 years. Pharmacological treatment, as it stands today, is a combination of preventive and symptomatic strategies. The mainstay life-saving drugs are angiotensin-converting enzyme inhibitors and β-blockers. Additional benefits are obtained when angiotensin-receptor blockers or aldosterone antagonists are added. Digitalis and/or diuretics are useful for symptom reduction. In addition, combination therapy with hydralazine and isosorbide dinitrate is recommended in African Americans.

KW - β-blockers

KW - Angiotensin-converting enzyme inhibitors

KW - Digitalis

KW - Diuretics

KW - Drugs

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=33747892889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747892889&partnerID=8YFLogxK

U2 - 10.1007/s10741-006-9482-z

DO - 10.1007/s10741-006-9482-z

M3 - Article

C2 - 16937030

AN - SCOPUS:33747892889

VL - 11

SP - 109

EP - 123

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 2

ER -

Access to Document

10.1007/s10741-006-9482-z